Novo Nordisk Unveils $23B Pipeline Plan, Investors Unimpressed as Shares Drop Over 7%

By Zhitong Finance

Novo Nordisk (NVO.US), the Denmark-based global pharmaceutical giant, has announced plans to launch more than five blockbuster drugs over the coming years as it strives to maintain competitiveness in an increasingly crowded obesity treatment market. Despite the company's pledge at its Capital Markets Day to deliver over $23 billion in new sales, its shares fell as much as 7.7% in early European trading. The company's U.S. ADR also weakened sharply in pre-market trading on Monday, dropping over 7%.

The $23 billion sales target appeared to fall short of market expectations. "Investors are selling shares because they didn't see any concrete new information that could drive Novo Nordisk's stock price higher," wrote Per Hansen, an investment economist at Nordnet, in a note.

Global Obesity Drug Market: Vast Untapped Demand

The global weight-loss drug market still holds enormous unmet demand, with long-term growth driven by rising treatment penetration and expanding indications. According to the World Health Organization, the global obese population exceeds 1 billion. Even with rapid capacity expansion, GLP-1 therapies are expected to cover less than 10% of the potential beneficiary population by 2030.

Investor Disappointment Despite New Drug Pipeline

After losing its absolute leadership in the booming obesity treatment market and being steadily overtaken by Eli Lilly, investors had hoped CEO Mike Doustdar would present a more concrete turnaround plan. The Danish drugmaker appears to have disappointed them.

Although Novo Nordisk pioneered a new generation of potent drugs that made obesity more treatable, it still lags behind Eli Lilly.

"We need to work harder, and we will," Doustdar said at an event in London. He stated that Novo Nordisk would explore acquisition opportunities while expanding its own R&D pipeline.

However, the presentation did not detail what specific factors would drive growth. Some expected growth comes from the next-generation product CagriSema, whose clinical trial results have repeatedly disappointed investors—including failing to match the efficacy of Eli Lilly's blockbuster weight-loss drug Zepbound in a head-to-head study.

Other potential growth drivers are compounds in earlier stages of development, which carry higher risks of failure.

In pushing for a more aggressive strategy, Doustdar has reduced headcount and management layers. Last week, the company removed "Nordisk" from its everyday name to boost brand recognition.

Patent Expiry and Competitive Pressures

A series of disappointing clinical trial results has led some investors to question whether the company can successfully grow as generic competition for its blockbuster drugs intensifies. Ozempic and Wegovy are expected to face patent expirations in Europe and the U.S. in the early 2030s.

Novo Nordisk previously stated that overall profit and revenue could decline by up to 6% this year.

The $100 Billion+ Obesity Drug Market: Entering the Final Phase

Mainstream institutional expectations for the global pure-play obesity drug market around 2030 range from approximately $95 billion to $105 billion. When including diabetes, cardiovascular, and other metabolic indications, the broader market ceiling could approach $200 billion.

• Goldman Sachs forecasts the global anti-obesity drug market at approximately $95 billion by 2030.
• Morgan Stanley projects a base case of $105 billion and a bull case of $144 billion. Starting from approximately $6 billion in sales in 2023, the base case implies a compound annual growth rate of about 50.5% from 2023 to 2030.
• JPMorgan estimates the global incretin market, including diabetes and obesity indications, will reach $200 billion by 2030, using a broader measurement and statistical scope.

Novo Nordisk's new drug blueprint reflects its intent to pursue the next wave of growth through product iteration. This target corresponds to future pipeline product sales contributions. The early trading decline of 7.7%, combined with investor calls for more specific growth targets, suggests the market is focused on when new drugs will launch, how they will differentiate, and how revenue growth will be sustained in the coming years. Facing competition from Eli Lilly and patent expirations on core products in the early 2030s, clear clinical, launch, and commercialization timelines will directly impact how the market values this long-term blueprint.

Long-Term Vision: Beyond Weight Loss

For obesity drug leaders Novo Nordisk and Eli Lilly, the long-term blueprint involves converting weight loss into sustainable health benefits and building a more complete metabolic disease treatment system. R&D endpoints will further cover cardiovascular events, worsening kidney function, metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, and joint pain and mobility.

Some expanded indications already have regulatory support:

• Novo Nordisk's Wegovy is approved to reduce the risk of serious cardiovascular events in eligible obese or overweight patients with cardiovascular disease.
• Zepbound has been approved to treat moderate-to-severe obstructive sleep apnea in obese adults.

Meanwhile, oral formulations, low-frequency long-acting dosing, better gastrointestinal tolerance, and weight maintenance regimens will remain competitive priorities. Investment value will increasingly concentrate on products that can demonstrate fat reduction, long-term treatment sustainability, and complication benefits—as this evidence helps expand the eligible population and strengthen payer acceptance.

Next-Generation Obesity Drugs: Focus on Efficacy and Quality

Next-generation obesity drugs will first focus on more substantial weight loss, higher-quality body composition improvement, and broader efficacy. Multi-target designs aim for deeper therapeutic effects by synergistically regulating appetite, satiety, blood sugar, and energy metabolism.

For example:

• Retatrutide (in development) simultaneously activates GLP-1, GIP, and glucagon receptors.
• Eli Lilly's TRIUMPH-1 Phase 3 results showed that the 12 mg group achieved an average weight loss of 28.3% at 80 weeks under the efficacy estimand assuming continued treatment, and 25.0% under the treatment policy estimand accounting for discontinuation.
• Novo Nordisk's zenagamtide (formerly amycretin), a single-molecule GLP-1/amylin dual receptor agonist, explores complementary satiety signaling.

Another R&D pathway aims to increase the proportion of fat loss while preserving lean body mass as much as possible, and to validate muscle strength and physical function benefits. The BELIEVE Phase 2 study of bimagrumab combined with semaglutide has already provided clinical evidence for this body composition optimization approach.